The purpose of this study is to see if a drug called sirolimus slows development of lymphangioleiomyomatosis (LAM), a lung disease in which abnormal cells growing inside the lungs prevent them from working properly.
Sirolimus is approved by the United States Food and Drug Administration (FDA) for the treatment of LAM. A recent trial showed that sirolimus stabilized lung function in patients with moderate and severe disease. Our researchers want to find out if giving low-dose sirolimus earlier in the course of treatment safely and effectively prevents further lung damage from LAM.